Evaluation of Index of Cardio-Electrophysiological Balance (iCEB) as a New Biomarker for the Identification of Patients at Increased Arrhythmic Risk

Annals of Noninvasive Electrocardiology

Volumn 21, Issue 3, 2016, Pages 294-304

  Robyns, Tomas ^a,b   Lu, Hua Rong ^c   Gallacher, David J ^c   Garweg, Christophe ^a,b   Ector, Joris ^a,b   Willems, Rik ^a,b   Janssens, Stefan ^a,b   Nuyens, Dieter ^a,b  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

cardiac wavelength; iCEB, risk stratification; index of cardio electrophysiological balance; sudden cardiac death

Indexed keywords

FLECAINIDE; SOTALOL; ANTIARRHYTHMIC AGENT; PHARMACOLOGICAL BIOMARKER;

ADULT; ARTICLE; ATRIAL FIBRILLATION; ATRIOVENTRICULAR NODAL REENTRY TACHYCARDIA; BRUGADA SYNDROME; CARDIOVASCULAR DISEASE ASSESSMENT; CLINICAL ARTICLE; CONTROLLED STUDY; ELECTROCARDIOGRAPHY; ELECTROPHYSIOLOGICAL PROCEDURES; FEMALE; HEART ARRHYTHMIA; HEART ATRIUM FLUTTER; HEART MUSCLE REFRACTORY PERIOD; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; INDEX OF CARDIOELECTROPHYSIOLOGICAL BALANCE; LONG QT SYNDROME; MALE; NON INVASIVE MEASUREMENT; PRIORITY JOURNAL; QRS INTERVAL; QT INTERVAL; SUPRAVENTRICULAR TACHYCARDIA; TORSADE DES POINTES; ARRHYTHMIAS, CARDIAC; DOSE RESPONSE; GENETICS; PATHOPHYSIOLOGY; RETROSPECTIVE STUDY; RISK ASSESSMENT;

ADULT; ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIAS, CARDIAC; BIOMARKERS, PHARMACOLOGICAL; BRUGADA SYNDROME; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROCARDIOGRAPHY; FEMALE; FLECAINIDE; HUMANS; LONG QT SYNDROME; MALE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SOTALOL;

EID: 84969941078     PISSN: 1082720X     EISSN: 1542474X     Source Type: Journal    
DOI: 10.1111/anec.12309     Document Type: Article

References (24)

1. Postema PG, Wilde AA,. The measurement of the QT interval. Curr Cardiol Rev 2014; 10: 287-294.
2. Lu HR, Yan GX, Gallacher DJ,. A new biomarker-index of cardiac electrophysiological balance (iCEB)-plays an important role in drug-induced cardiac arrhythmias: Beyond QT-prolongation and torsades de pointes (TdPs). J Pharmacol Toxicol Methods 2013; 68: 250-259.
3. Robert E, Aya AG, de la Coussaye JE, et al., Dispersion-based reentry: Mechanism of initiation of ventricular tachycardia in isolated rabbit hearts. Am J Physiol 1999; 276: H413-H423.
4. Aidonidis I, Poyatzi A, Stamatiou G, et al., Dose-related shortening of ventricular tachycardia cycle length after administration of the Katp channel opener bimakalim in a 4-day-old chronic infarct anesthetized pig model. J Cardiovasc Pharmacol Ther 2009; 14: 222-230.
5. Lu HR, Hermans AN, Gallacher DJ,. Does terfenadine-induced ventricular tachycardia/fibrillation directly relate to its QT prolongation and torsades de pointes ? Br J Pharmacol 2012; 166: 1490-1502.
6. King JH, Huang CL, Fraser JA,. Determinants of myocardial conduction velocity: Implications for arrhythmogenesis. Front Physiol 2013; 4: 154.
7. Guss SB, Kastor JA, Josephson ME, et al., Human ventricular refractoriness. Effects of cycle length, pacing site and atropine. Circulation 1976; 53: 450-455.
8. Olsson B, Brorson L, Harper R, et al., Estimation of ventricular refractoriness in man by the extra stimulus method. Cardiovasc Res 1977; 11: 31-38.
9. Voss F, Becker R, Bauer A, et al., Are QT measurements on body surface ecg indicative of ventricular refractory patterns? Basic Res Cardiol 2005; 100: 22-27.
10. Roden DM., Drug-induced prolongation of the QT interval. N Engl J Med 2004; 350: 1013-1022.
11. Osadchii OE., Flecainide-induced proarrhythmia is attributed to abnormal changes in repolarization and refractoriness in perfused guinea-pig heart. J Cardiovasc Pharmacol 2012; 60: 456-466.
12. Osadchii OE., Effects of Na+ channel blockers on extrasystolic stimulation-evoked changes in ventricular conduction and repolarization. J Cardiovasc Pharmacol 2014; 63: 240-251.
13. Priori SG, Wilde AA, Horie M, et al., Executive summary: HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes. Europace 2013; 15: 1389-1406.
14. Shah RR, Morganroth J, Kleiman RB,. Ich e14 q&a(r2) document: Commentary on the further updated recommendations on thorough QT studies. Br J Clin Pharmacol 2015; 79: 456-464.
15. Laverty H, Benson C, Cartwright E, et al., How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines? Br J Pharmacol 2011; 163: 675-693.
16. Kanters JK, Haarmark C, Vedel-Larsen E, et al., T(peak)T(end) interval in long QT syndrome. J Electrocardiol 2008; 41: 603-608.
17. Anderson JL, Prystowsky EN,. Sotalol: An important new antiarrhythmic. Am Heart J 1999; 137: 388-409.
18. Lu HR, Rohrbacher J, Vlaminckx E, et al., Predicting drug-induced slowing of conduction and pro-arrhythmia: Identifying the 'bad' sodium current blockers. Br J Pharmacol 2010; 160: 60-76.
19. Malik M., QT/RR hysteresis. J Electrocardiol 2014; 47: 236-239.
20. Horr S, Goldenberg I, Moss AJ, et al., Ion channel mechanisms related to sudden cardiac death in phenotype-negative long-QT syndrome genotype-phenotype correlations of the KCNQ1(s349w) mutation. J Cardiovasc Electrophysiol 2011; 22: 193-200.
21. Chiladakis J, Kalogeropoulos A, Zagkli F, et al., Effect of heart rate on the intrinsic and the ventricular-paced QRS duration. J Electrocardiol 2015.
22. Nemec J, Buncová M, Bůlková V, et al., Heart rate dependence of the QT interval duration: Differences among congenital long QT syndrome subtypes. J Cardiovasc Electrophysiol 2004; 15: 550-556.
23. Sangawa M, Morita H, Nakatsu T, et al., Abnormal transmural repolarization process in patients with Brugada syndrome. Heart Rhythm 2009; 6: 1163-1169.
24. Malik M, Färbom P, Batchvarov V, et al., Relation between QT and RR intervals is highly individual among healthy subjects: Implications for heart rate correction of the QT interval. Heart 2002; 87: 220-228.